Long-term Outcomes and Prognostic Markers in Gallbladder Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Jul 12

PMID 29995783

Citations 11

Authors

Xiwei Cui

Sha Zhu

Zhihang Tao

Xinghao Deng

Yexiao Wang

Yuanjing Gao

Yue Liao

Weijun Ma

Yiwen Zhang

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Cancer-related inflammation and systemic inflammatory markers have been widely recognized as an essential part in tumor multiplication, invasion, and metastasis of tumor cells. This study aimed to estimate and compare the prognostic value of various biomarkers on overall survival (OS) in patients with gallbladder cancer patients.We performed a retrospective study of 159 patients received different therapies in West China Hospital from 2009 to 2014. The preoperative biomarker data, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), lactate dehydrogenase, and alkaline phosphatase, as well as other clinical information, were obtained from electronic record. And the receiver operating characteristic curves were used to analyze the optimal cut-off values of them. Kaplan-Meier survival analysis and Cox proportional hazard model analysis were applied to evaluate the association between markers and OS.The optimal cut-off value was 4.39 for NLR, 181.85 for PLR, 0.30 for MLR, and 3.02 for carcinoembryonic antigen (CEA). Kaplan-Meier analysis and univariate Cox analysis both demonstrated the significant prognostic value of NLR, MLR, and CEA. However, PLR failed to be a significant predictor of OS. The multivariate Cox analysis showed that preoperative NLR and CEA were independent prognostic factors for OS.Advanced tumor/node/metastasis stage, enhanced pretherapeutic NLR, and CEA were significantly associated with worse OS of gallbladder cancer patients. Furthermore, NLR was a better prognostic factor than CEA in advanced T (T3-T4) stage patients, while CEA was better for early T (T1-T2) stage, early N (N0-N1) stage, and early M (M0) stage patients.

Citing Articles

Prognostic value of preoperative fibrinogen to albumin ratio in predicting postoperative outcomes in patients with gallbladder cancer.

Wang P, Duan Y World J Gastrointest Surg. 2025; 17(2):100728.

PMID: 40061970 PMC: 11886017. DOI: 10.4240/wjgs.v17.i2.100728.

A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies.

Koc D, Manescu I, Manescu M, Dobreanu M Diagnostics (Basel). 2024; 14(18).

PMID: 39335736 PMC: 11431542. DOI: 10.3390/diagnostics14182057.

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.

Cheng Z, Yang C, Zhao Q, Zhong J, Zhang J, Jin R Cancer Sci. 2024; 115(6):1979-1988.

PMID: 38487949 PMC: 11145113. DOI: 10.1111/cas.16142.

Haematologic biomarkers and survival in gallbladder cancer: a systematic review and meta-analysis.

Velasco Jr R, Tan H, San Juan M Ecancermedicalscience. 2024; 18:1660.

PMID: 38425767 PMC: 10901636. DOI: 10.3332/ecancer.2024.1660.

Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer.

Lopez E, Hidalgo S, Roa E, Gomez J, Hermansen Truan C, Sanders E Oncoimmunology. 2023; 12(1):2225291.

PMID: 37363103 PMC: 10288912. DOI: 10.1080/2162402X.2023.2225291.

References

Andrade S, Sumikawa J, Castro E, Batista F, Paredes-Gamero E, Oliveira L . Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. Oncotarget. 2017; 8(10):16851-16874. PMC: 5370006. DOI: 10.18632/oncotarget.15170. View

Ying H, Deng Q, He B, Pan Y, Wang F, Sun H . The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014; 31(12):305. DOI: 10.1007/s12032-014-0305-0. View

Powell D, Huttenlocher A . Neutrophils in the Tumor Microenvironment. Trends Immunol. 2015; 37(1):41-52. PMC: 4707100. DOI: 10.1016/j.it.2015.11.008. View

Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I . Collaborating with the enemy: function of macrophages in the development of neoplastic disease. Mediators Inflamm. 2013; 2013:831387. PMC: 3613099. DOI: 10.1155/2013/831387. View

Mouchemore K, Anderson R, Hamilton J . Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. 2017; 285(4):665-679. DOI: 10.1111/febs.14206. View

Thomas G, Tacke R, Hedrick C, Hanna R . Nonclassical patrolling monocyte function in the vasculature. Arterioscler Thromb Vasc Biol. 2015; 35(6):1306-16. PMC: 4441550. DOI: 10.1161/ATVBAHA.114.304650. View

Caporarello N, Lupo G, Olivieri M, Cristaldi M, Cambria M, Salmeri M . Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review). Mol Med Rep. 2017; 16(4):4393-4402. PMC: 5646999. DOI: 10.3892/mmr.2017.7179. View

Feng F, Tian Y, Liu S, Zheng G, Liu Z, Xu G . Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors. Medicine (Baltimore). 2016; 95(14):e3248. PMC: 4998783. DOI: 10.1097/MD.0000000000003248. View

Cassetta L, Pollard J . Cancer immunosurveillance: role of patrolling monocytes. Cell Res. 2015; 26(1):3-4. PMC: 4816132. DOI: 10.1038/cr.2015.144. View

10.

Jaruvongvanich V, Yang J, Peeraphatdit T, Roberts L . The incidence rates and survival of gallbladder cancer in the USA. Eur J Cancer Prev. 2017; 28(1):1-9. DOI: 10.1097/CEJ.0000000000000402. View

11.

Liu W, Guo W, Shen L, Chen Z, Luo Q, Luo X . T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice. Oncotarget. 2016; 8(5):7586-7597. PMC: 5352345. DOI: 10.18632/oncotarget.13812. View

12.

Hanna R, Cekic C, Sag D, Tacke R, Thomas G, Nowyhed H . Patrolling monocytes control tumor metastasis to the lung. Science. 2015; 350(6263):985-90. PMC: 4869713. DOI: 10.1126/science.aac9407. View

13.

Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Mori K . Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016; 103(7):891-8. DOI: 10.1002/bjs.10123. View

14.

Li A, Karlan B . Androgen mediation of thrombocytosis in epithelial ovarian cancer biology. Clin Cancer Res. 2005; 11(22):8015-8. DOI: 10.1158/1078-0432.CCR-05-1058. View

15.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W . Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017; 111:176-181. DOI: 10.1016/j.lungcan.2017.07.024. View

16.

Fu B, Fu Z, Meng W, Gu T, Sun X, Zhang Z . Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients. Tumour Biol. 2015; 36(8):6477-83. DOI: 10.1007/s13277-015-3338-x. View

17.

Uemura K, Kawahara T, Yamashita D, Jikuya R, Abe K, Tatenuma T . Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. Biomed Res Int. 2017; 2017:7538647. PMC: 5602619. DOI: 10.1155/2017/7538647. View

18.

Hurt B, Schulick R, Edil B, El Kasmi K, Barnett Jr C . Cancer-promoting mechanisms of tumor-associated neutrophils. Am J Surg. 2017; 214(5):938-944. DOI: 10.1016/j.amjsurg.2017.08.003. View

19.

Yoshihama S, Roszik J, Downs I, Meissner T, Vijayan S, Chapuy B . NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016; 113(21):5999-6004. PMC: 4889388. DOI: 10.1073/pnas.1602069113. View

20.

Mitin T, Enestvedt C, Jemal A, Sineshaw H . Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst. 2017; 109(7). DOI: 10.1093/jnci/djw324. View